These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 27475719

  • 1. Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation.
    Zeybel GL, Pearson JP, Krishnan A, Bourke SJ, Doe S, Anderson A, Faruqi S, Morice AH, Jones R, McDonnell M, Zeybel M, Dettmar PW, Brodlie M, Ward C.
    J Cyst Fibros; 2017 Jan; 16(1):124-131. PubMed ID: 27475719
    [Abstract] [Full Text] [Related]

  • 2. GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).
    Davies JC, Van de Steen O, van Koningsbruggen-Rietschel S, Drevinek P, Derichs N, McKone EF, Kanters D, Allamassey L, Namour F, de Kock H, Conrath K.
    J Cyst Fibros; 2019 Sep; 18(5):693-699. PubMed ID: 31147302
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.
    Taylor-Cousar J, Niknian M, Gilmartin G, Pilewski JM, VX11-770-901 investigators.
    J Cyst Fibros; 2016 Jan; 15(1):116-22. PubMed ID: 25682022
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, Waltz D, Wainwright CE, VX-809 TRAFFIC and TRANSPORT study groups.
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis.
    Shakir S, Echevarria C, Doe S, Brodlie M, Ward C, Bourke SJ.
    J Cyst Fibros; 2022 Sep; 21(5):807-810. PubMed ID: 35718668
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC, Sermet-Gaudelus I, Naehrlich L, Harris RS, Campbell D, Ahluwalia N, Short C, Haseltine E, Panorchan P, Saunders C, Owen CA, Wainwright CE, VX16-661-115 Investigator Group.
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
    Bernarde C, Keravec M, Mounier J, Gouriou S, Rault G, Férec C, Barbier G, Héry-Arnaud G.
    PLoS One; 2015 Jan; 10(4):e0124124. PubMed ID: 25853698
    [Abstract] [Full Text] [Related]

  • 14. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.
    Edgeworth D, Keating D, Ellis M, Button B, Williams E, Clark D, Tierney A, Heritier S, Kotsimbos T, Wilson J.
    Clin Sci (Lond); 2017 Aug 01; 131(15):2037-2045. PubMed ID: 28611235
    [Abstract] [Full Text] [Related]

  • 15. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
    Gomez-Pastrana D, Nwokoro C, McLean M, Brown S, Christiansen N, Pao CS.
    An Pediatr (Engl Ed); 2019 Mar 01; 90(3):148-156. PubMed ID: 30093322
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT, VX11-661-101 Study Group.
    Am J Respir Crit Care Med; 2018 Jan 15; 197(2):214-224. PubMed ID: 28930490
    [Abstract] [Full Text] [Related]

  • 19. Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study.
    Nick JA, St Clair C, Jones MC, Lan L, Higgins M, VX12-770-113 Study Team.
    J Cyst Fibros; 2020 Jan 15; 19(1):91-98. PubMed ID: 31784217
    [Abstract] [Full Text] [Related]

  • 20. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.
    Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G, VX15-661-113 Investigator Group.
    J Cyst Fibros; 2019 Sep 15; 18(5):708-713. PubMed ID: 31253540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.